Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cystic Fibrosis
Inspire Announces Peer-reviewed Publications Related To Denufosol for Cystic Fibrosis
August 23rd, 2008
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced publication of two papers related to the denufosol for cystic fibrosis development program in peer-reviewed journals. The first paper, "Denufosol: A Review of Studies with Inhaled P2Y2 Agonists that led to Phase 3" (D. Kellerman, A. Rossi Mospan, J. Engels, A. Schaberg, J. Gorden, L. Smiley), was published in Pulmonary Pharmacology & Therapeutics August 2008, Volume 21, Issue 4; pgs 600-607. This review included previously published results from Phase 1 and 2 clinical trials with denufosol. Key findings highlighted in the paper provide rationale for the...
Source: Law & Health Weekly (2008-08-23)
|
